Amid the wave of high-profile departures in the 2026 biotech industry, this one stands as the most seismic.

The Şahin couple’s entrepreneurial journey has become legendary in biopharma. Back in 2001, they founded Ganymed Pharmaceuticals, which they later sold to Astellas for $460 million—gaining invaluable experience and resources for their next venture, BioNTech.

When BioNTech was founded in 2008, mRNA technology was not its core focus. The company gradually built its technological platform through a series of strategic acquisitions:

• 2009: acquired EUFETS and JPT Peptide Technologies, establishing GMP capabilities and a peptide research tool platform
• 2010: acquired Microbody technology, strengthening its nanoparticle expertise

The real turning point came in 2013, when Katalin Karikó, one of the pioneers of mRNA vaccine technology, joined as Vice President. BioNTech filed multiple mRNA-related patents in 2014 and gradually developed its proprietary mRNA development platform.

Alongside technological accumulation, BioNTech solidified its industry position through precise strategic collaborations. Between 2015 and 2019, it partnered with pharmaceutical giants including Eli Lilly, Genentech, Sanofi, and Pfizer. Its long-term collaboration with Pfizer laid the groundwork for the rapid development of the COVID-19 vaccine.

BioNTech listed on the Nasdaq in 2019. Few could have predicted that this biotech company, valued at around $3 billion, would soon rewrite the history of human medicine.

In January 2020, when the genetic sequence of the novel coronavirus was released, Şahin recognized this as mRNA’s moment to prove itself. BioNTech quickly launched “Project Lightspeed,” devoting all company resources to COVID-19 vaccine development.

In less than 10 months, BioNTech and partner Pfizer completed vaccine development, large-scale clinical trials, and emergency use authorization—setting the record for the fastest vaccine development against a new pathogen in medical history. BNT162b2 became the world’s first approved mRNA COVID-19 vaccine.

The commercial success of the COVID-19 vaccine was undeniable.By July 2021, BioNTech had supplied more than 1 billion doses and secured agreements for 2.2 billion doses, generating €15.9 billion in vaccine revenue that year. At its peak in 2021, BioNTech achieved annual revenue of €19 billion and a net profit of €10.293 billion.

However, as sales of its only marketed product—the COVID-19 vaccine—continued to shrink, BioNTech’s financial outlook grew increasingly grim.

In 2025, the company reported full-year revenue of €2.9 billion, a net loss of €1.1 billion (adjusted net loss €100 million), and a diluted loss per share of €4.70 ($5.53) (adjusted diluted loss per share €0.48, or ~$0.55).

Meanwhile, the company projected that amid the continued decline of the COVID-19 vaccine market, 2026 total revenue would range from €2.0 billion to €2.3 billion, adjusted R&D expenses from €2.2 billion to €2.5 billion, and adjusted selling and administrative expenses from €700 million to €800 million.

The era of explosive growth is definitively over. BioNTech must now prove to the market that it can generate sustainable value in oncology.

From this perspective, the Şahins’ departure becomes more understandable.

At a critical juncture of strategic transition, with late-stage assets such as BNT327 maturing toward commercialization, BioNTech may now need a CEO with decades of global commercialization experience at large multinational pharma companies—not a lab-focused innovator.

In the press release, CEO Şahin framed the unexpected career move as an opportunity to “pass the baton.”

“Over the past 18 years, we have built BioNTech from a startup into a global biopharmaceutical company with a strong and diversified pipeline,” the CEO explained in a statement. “Today, the company is ready to advance its mission and evolve into a commercial multi-product company.”

“At the same time, Özlem and I are ready to be pioneers again,” Şahin added. “Our vision has always been to translate our science into meaningful progress for patients, and we see an extraordinary opportunity to unlock the next generation of transformative innovation.”

The two founders will launch their third biotechnology company, a next-generation mRNA firm focused on cutting-edge platform technologies and disruptive mRNA innovation.

BioNTech will grant the new company certain rights and access to mRNA technology in exchange for a minority equity stake, milestone payments, and royalties. The arrangement aims to create collaborative opportunities for complementary or synergistic therapeutic strategies. A binding agreement is expected to be signed by the end of the first half of 2026.

BioNTech is in a critical transition from a “founder-led research organization” to an “industrialized global oncology pharma company.”In this new phase, the Şahins’ departure and launch of a new mRNA firm represent a “split strategy” designed to create greater shareholder value—separating capital-intensive early-stage R&D from commercial operations that require stable cash flow.

Analysts at Leerink Partners described the co-founders’ decision as “a logical step as the company advances toward its goal of multiple product launches by 2030.”

“However, we recognize this injects significant uncertainty into a stock already under pressure to deliver late-stage oncology assets,” the analysts added. “In the near term, we see uncertainty from leadership vacancy while the board completes the selection of new management.”

The urgency of transformation is clearly reflected in BioNTech’s 2026 strategic plan.

Şahin explicitly stated that 2026 will be a “catalyst year” where scientific research translates into tangible commercial results. The core goal is to transition the company from the single-product COVID-19 vaccine era into a truly multi-product, cross-tumor innovative biopharma enterprise.

This strategy centers on three pillars:

• cancer immunotherapy
• antibody-drug conjugates (ADCs)
• mRNA immunotherapies

Its oncology pipeline has “entered a harvest phase”:By the end of 2026, BioNTech plans to have 15 ongoing Phase III trials and release data from 7 late-stage programs, which will directly support the Biologics License Applications (BLAs) for its first oncology products.

Key Assets

A PD-(L)1/VEGF bispecific antibody from China’s Promisome Therapeutics. Last June, it attracted a $1.5 billion upfront payment from BMS (Bristol-Myers Squibb) and remains BioNTech’s flagship asset, with 8 global Phase III trials planned by the end of 2026.

BioNTech reaffirmed its three-step strategy—Establish, Expand, Elevate—for BNT327 in prior investor meetings:

• Establish: Phase III trials in small-cell lung cancer, non-small cell lung cancer, and triple-negative breast cancer
• Expand: 12 studies covering more than 10 new indications including gastric, colorectal, liver, and head and neck cancers
• Elevate: combination trials with HER2, B7-H3, Trop2 ADCs, and novel immune-targeted agents

A selective CTLA-4 Treg modulator. In March 2023, BioNTech partnered with OncoC4 for $200 million upfront. OncoC4 was founded by a Chinese-American scientist couple, headquartered in Maryland with operations in China.

A global Phase III trial is underway in metastatic squamous NSCLC patients who progressed after platinum-based chemotherapy and PD-(L)1 inhibition.In December 2025, data from the first stage (non-pivotal dose confirmation) showed clinically meaningful overall survival benefit and manageable safety versus chemotherapy.

Interim data from the pivotal stage is expected in 2026. In January 2026, gotistobart was granted Orphan Drug Designation by the FDA for squamous NSCLC.

An anti-HER2 ADC candidate in-licensed from BioMap Biotech in April 2023 for $170 million upfront, with a total deal value over $1.5 billion.

A Phase I/II trial is ongoing in advanced HER2-expressing tumors, with a potential registration cohort in recurrent HER2-expressing endometrial cancer. BioNTech and BioMap aim to submit a BLA in 2026, subject to FDA feedback.A global Phase III trial in HR+, HER2-low metastatic breast cancer is ongoing, with data expected in 2026.

Another ADC from BioMap, targeting B7H3. A Phase III trial comparing BNT324 vs docetaxel in mCRPC is expected to start in 2026.

Updated Phase I/II data was presented at the 2026 ASCO GU symposium: BNT324/DB-1311 showed durable efficacy in heavily pre-treated mCRPC patients with no new safety signals.

An mRNA cancer vaccine encoding the HPV16 oncoproteins E6 and E7, designed to trigger a precise immune response in HPV16+ head and neck squamous cell carcinoma (HNSCC).

In December 2025, the FDA granted Fast Track Designation for BNT113 in PD-L1+, HPV16+ HNSCC.In 2026, initial interim analysis is expected from a Phase II/III trial comparing BNT113 plus pembrolizumab vs pembrolizumab alone in first-line treatment of unresectable recurrent or metastatic PD-L1+, HPV16+ HNSCC.

An individualized mRNA neoantigen vaccine developed with Genentech (Roche).

An updated Phase II readout in adjuvant ctDNA-positive Stage II (high-risk) / Stage III colorectal cancer is expected in early 2026. Due to slower-than-expected enrollment, final analysis was pushed from 2026 to 2027.

Amid shifting treatment standards, BioNTech and Roche discontinued one Phase II trial, focusing instead on ongoing randomized Phase II trials in adjuvant pancreatic ductal adenocarcinoma and adjuvant CRC.

A close review of BioNTech’s heavily invested oncology and ADC pipeline reveals that Chinese biotechs and assets have become the core engine of its transformation.

As the old pillars—COVID-19 vaccines and founding leaders—step back, BioNTech’s fate now hinges heavily on these assets from across the Pacific.

• Can BNT327, backed by BMS, become a next-generation IO cornerstone?
• Can BioMap’s ADC portfolio successfully advance and solidify a major position in solid tumors?
• Can OncoC4’s differentiated CTLA-4 capture meaningful share in the NSCLC market?

As the pioneers of mRNA return to their roots to start anew, the German giant—with €17.2 billion in cash—must continue to prove it can deliver not only a world-changing vaccine, but also build a lasting presence in cancer immunotherapy.